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Abstract
The addition of ATP, but not ADP or AMP, to the culture media of bovine nasal cartilage explants caused an
acceleration in the rate of proteoglycan loss from the tissue. The ATP-stimulated loss of proteoglycan was not inhibited by
the IL1-receptor antagonist protein, but was partially inhibited by the presence of ADP or AMP. The proteolytic events
resulting from the presence of ATP were found to be similar to those following treatment with IL1, in that inhibitors of the
cysteine-peptidase cathepsin B, serine-proteinases with trypsin-like specificity, and of some of the matrixins, could all
prevent proteoglycan loss, which was mediated, at least in part, by the action of ‘aggrecanase’. In contrast to its effects on
nasal cartilage, ATP inhibited basal and stimulated proteoglycan release from articular cartilage. Both ADP and AMP had
no effect on proteoglycan release in articular cartilage but enhanced the response to ATP when added concurrently. We
conclude that extracellular ATP, probably acting via P -purinoceptors, stimulates proteoglycan breakdown from bovine2
nasal cartilage and thus, may have a role in diseases which primarily involve destruction of non-articular cartilage.
Extracellular ATP has, in contrast, a chondroprotective effect on bovine articular cartilage. q 1997 Elsevier Science B.V.
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1. Introduction
The major extracellular components of cartilage;
proteoglycan and type II collagen, form a matrix
which is synthesised and maintained by the chondro-
cytes embedded within it. Loss of proteoglycan and
its associated water can compromise the structure and
function of cartilage by reducing its resilience to
compressive loading and increasing friction during
w xjoint motion 1,2 . Depletion of cartilage proteogly-
can may predispose the cartilage to further mechani-
cal damage resulting in collagen loss. It is important,
therefore, to identify factors which exert metabolic
control over proteoglycan turnover.
As well as its crucial intracellular role, it has
become evident that ATP may have a number of
functions outside the cell. ATP binds to P -purinocep-2
tors at the cell surface. These receptors can be di-
vided into several subtypes on the basis of their
pharmacological characteristics, signal transduction
w xmechanisms and protein structure 3–5 .
ATP is present in millimolar concentrations in the
cytosol of eucaryotic cells, but extracellular levels are
normally very low. Extracellular ATP is hydrolysed
by ectophosphatases such as ecto-ATPase
 .  .E.C.3.6.1.3 and NTP pyrophosphatase E.C.3.6.1.8
w x5 . The activity of ectophosphatases present at the
surface of cells which also express ATP receptors
will affect the concentration of extracellular nu-
cleotides and hence, the cells’ response to them.
There is increasing evidence that extracellular
purines may have a role in regulating cartilage func-
tion. ATP can stimulate PGE production in human2
articular chondrocytes, suggesting the presence of
w xP -purinoceptors on the chondrocyte surface 6,7 .2
Ecto-nucleoside triphosphate pyrophosphatase activ-
ity, catalysing the reaction of ATP to AMP and PPi,
has been demonstrated on human articular chondro-
w xcytes in vitro 8 . ATP has been detected in the
synovial fluid of patients with osteoarthritis and
rheumatoid arthritis, and is elevated in patients with
calcium pyrophosphate dihydrate crystal deposition
w xdisease, as in chondrocalcinosis 9 . Finally, it has
been demonstrated that extracellular ATP accelerates
the loss of proteoglycan from bovine nasal septum
w xcartilage explants 10 . We have now followed up this
latter observation with a more detailed study of the
effects of extracellular ATP on proteoglycan




 .The matrixin inhibitors BB94 Batimastat , BB87,
w xBB250, BB3003 and BB2001 11,12 , were synthe-
sised and supplied by British Biotech Pharmaceuti-
cals, Oxford, UK. ACITIC was a gift from Prof. J.C.
Powers, School of Chemistry and Biochemistry,
Georgia Institute of Technology, Atlanta, USA. The
cysteine proteinase inhibitors CaO74Me and Ep453
were gifts from Dr. M. Murata, Research Centre,
Taisho Pharmaceutical, Ohmiya-shi, Saitama 330,
 7 .Japan. RhIL1a specific activity 5=10 unitsrmg
was a gift from Dr. K. Ray of Glaxo Group Research,
Greenford, Middlesex, UK and rhTNFa specific
7 .activity 8=10 unitsrmg was kindly provided by
Dr. E. Amento, Genentech, Boulder, CO, USA. Ret,
gentamycin, cortisol, chondroitin sulfate A, p-
aminophenylmercuric acid, ATP vanadate-free, cata-
.logue number A2383 , ADP, AMP, antibody to PGE
and 8-phenyltheophylline were from Sigma, Poole,
Dorset, UK. DMEM, NCS, amphotericin B, peni-
cillin and streptomycin were purchased from Gibco
Life Sciences, Paisley, UK. Mca-Pro-Leu-Gly-Leu-
Dpa-Ala-Arg-NH was provided by Dr. C.Graham2
Knight, Strangeways Research Laboratory, Cam-
35 w35 xbridge, UK. SO and S -methionine were prod-4
ucts of Amersham International plc, Little Chalfont,
Buckinghamshire, UK. Antibody BC3 was a gift
from Drs. B. Caterson and C. Hughes, Connective
Tissue Biology Lab, School of Molecular and Medi-
cal Biosciences, University of Wales, Cardiff, UK,
while goat anti-mouse IgG was purchased from
Southern Biotechnology Associates, Oxmoor Boule-
vard, Birmingham, UK. CPC was obtained from BDH
Merck, Merck House, Poole, Dorset, UK. Chondroiti-
 .nase ABC lyase EC.4.2.2.4 , antibody 3B3 and ker-
 .atanase EC.3.2.1.103 were from ICN Biomedicals,
Thame Park Business Centre, Thame, Oxfordshire,
 . UK. 40% wrv AcrylamiderBis solution 37.5
X .acrylamide:1 N,N -methylenebisacrylamide and al-
 .kaline phosphatase EC. 3.1.3.1 conjugate substrate
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kit were provided by BioRad, BioRad House, Hemel
Hempstead, Hertfordshire, UK. 1,9-Dimethylmethyl-
ene blue was from Aldrich, New Road, Gillingham,
Dorset, UK. IL1ra was from Synergen, Boulder, USA.
All buffers and salts were of analytical grade.
2.2. Cartilage cultures
Bovine nasal septum cartilage was prepared and
w xpreincubated as described previously 13 . The carti-
lage discs were then transferred individually to wells
of a 96-well plate each containing 195ml of DMEM
to which ATP, its metabolites, or ATPgS were added
from 40-fold concentrated stock solutions in PBS.
ATP was added either every 24 h or as a single dose
at the start of the culture period. The cultures were
maintained at 378C in a humidified atmosphere of 5%
CO for 5 days with a medium change after 2 days.2
The media and discs were stored frozen awaiting
analysis.
Articular cartilage was dissected and preincubated
w xas described previously 14 after which the explants
were treated as described above.
2.3. Determination of ATP hydrolysis
An equal number of explants was placed in each of
two petri dishes, in 25 ml DMEM. To one dish, ATP
was added to give a final concentration of 500 mM.
This concentration of ATP was also added to a third
dish which contained no explants and acted as a
 .control. Medium 400 ml was removed from the
cultures at specific times, frozen in liquid N and2
stored at y708C awaiting analysis.
The concentration of extracellular ATP remaining
in the media after various times was determined by
anion-exchange chromatography. The medium was
run on to a 1 ml Mono Q anion-exchange column
 .connected to the fplc system Pharmacia and eluted
using a gradient of ammonium hydrogen carbonate as
w xdescribed previously 15 . ATP was detected at
254 nm. The elution time for ATP was determined by
comparison with an authentic standard. The relative
concentration of ATP in the media at various time
points was found by comparing the peak height to
that recorded for a known concentration of ATP.
From this the half-life of ATP was determined, as-
suming first order decay.
2.4. Measurement of proteoglycan breakdown
The amount of proteoglycan in the medium of
cartilage explants was determined as sGAG by adap-
w xtation of the method of Farndale et al. 16 for use
w xwith a plate reader 17 . The binding of sGAG to the
dye was accompanied by a metachromatic shift, mea-
sured as a decrease in absorbance at 570 nm. Deter-
mination of residual sGAG in the cartilage explants
was by the same method following digestion with
papain.
2.5. Time-course for the effect of added ATP on
proteoglycan release from bo˝ine nasal cartilage
cultures
Two cartilage explants and 500 ml DMEM were
placed into each well of a 48-well plate. ATP was
added from a 40-fold concentrated stock solution in
PBS, to give a final concentration of 500 mM. The
medium was removed at various times, the explants
washed twice in DMEM, and then cultured for the
remaining time in DMEM without ATP. The medium
was changed after 2 days.
2.6. Addition of inhibitors to ATP-treated bo˝ine
nasal cartilage explants
Cartilage explants were transferred individually to
wells of a 96-well plate, together with 195ml of
serum-free DMEM. 8-Phenyltheophylline, IL1ra, and
inhibitors of metallo-, cysteine- or serine-proteinases
were added from 100-fold concentrated stock solu-
tions. Stock solutions of the metallo-proteinase in-
 .hibitors BB87, BB94, BB250, BB3003 and BB2001
were made in methanol, the cysteine Ep453,
.  .CaO74Me and serine-proteinase ACITIC inhibitors
were dissolved in DMSO, and 8-phenyltheophylline
 .was dissolved in methanolr1M NaOH 4:1 vrv .
After 1 h ATP, rhIL1a or rhTNFa were added to
final concentrations of 500 mM, 0.3 or 3.5 nM, re-
spectively. For the experiments with 8-phenyltheo-
phylline and IL1ra, the cultures were maintained for
5 days with a medium change on day 2, whereas for
the experiments with the enzyme inhibitors, the cul-
tures were maintained for 2 days.
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2.7. Assay of matrixin acti˝ity
Matrixin activity was determined as previously
w xdescribed 11 by use of the quenched fluorescent
substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2
 .5 mM which is cleaved by all the secreted matrixins
w xso far tested 11 . Activity in conditioned medium
 .from explants cultured with or without ATP 500 mM
for 5 days, with or without APMA activation 0.1 mM;
.1 h of putative promatrixins, was assessed by contin-
uous rate assays at 378C.
2.8. Detection of an ‘aggrecanase’-generated
proteoglycan clea˝age product
Bovine nasal cartilage explants were dissected and
preincubated as described above. Half the explants
 .f100 were placed in a petri dish containing 25 ml
 .DMEM and ATP 500 mM . The remaining explants
were placed in another petri dish containing DMEM
alone. The explants were cultured for 5 days with a
medium change on day 2. At the end of each culture
period proteinase inhibitors 8 mgrml soyabean
trypsin inhibitor, 0.1 M amino-n-caproic acid, 0.1 M
EDTA, 0.1 M benzamidine HCl, 0.1 M PMSF, 0.2 M
.iodoacetic acid were added to the conditioned media.
 .NaN 0.03 M was added as a preservative, and the3
medium was stored at y408C awaiting analysis.
Samples were dialysed into deglycosylation buffer
 .0.1 M Tris, 0.1 M sodium acetate, pH 7.0 , concen-
trated 2-fold using Centricon spin concentrators and
w x deglycosylated 18 . Loading buffer 30 mM Tris con-
 .taining 2% wrv SDS, 0.001% bromophenol blue,
 . .  .10% vrv glycerol and mercaptoethanol 5% were
added to the samples which were then boiled for
5 min. Equal volumes of the conditioned media were
run on 4–10% gradient SDS–polyacryamide gels and
electro-transferred onto PVDF membranes as de-
w xscribed previously 19 . The membranes were placed
  . .in blocking buffer PBS with 5% vrv horse serum
overnight, after which they were incubated with pri-
 .mary antibody, either 3B3 1:256 which detects the
disaccharide stubs remaining after chondroitinase
w x  .treatment 20 or BC3 1:1000 which detects the
N-terminal neoepitope resulting from cleavage of
proteoglycan by ‘aggrecanase’ in the interglobular
w xregion 21 for 1 h. After incubation with the sec-
 .ondary antibody 1:500 for 1 h, bands were detected
using the BioRad alkaline phosphatase conjugate sub-
strate kit.
2.9. Proteoglycan synthesis
Bovine nasal cartilage explants were incubated
with or without single doses of extracellular ATP
 .  .500 mM and rhIL1a 0.3 nM for 5 days as de-
scribed above. The explants were then pulsed for 6 h
with 5 mCirml 35SO under the same culture condi-4
w xtions, and treated as described previously 22 .
2.10. Protein synthesis
w35 xThis was assayed by the incorporation of S -
methionine into trichloroacetic acid-precipitable ma-
w xterial, as described elsewhere 11 .
2.11. Lactate determination
The concentration of lactate in the medium was
determined using a kit supplied by Sigma. which
utilises the lactate oxidaserperoxidase method.
2.12. Determination of PGE released by bo˝ine nasal
cartilage explants
Cartilage explants were incubated as described
w xpreviously 10 , and proteoglycan release was deter-
mined. PGE was quantified in the medium by ra-
w xdioimmunoassay 6 .
2.13. Statistical analyses
Each experiment was repeated at least twice using
tissue from different animals. Qualitatively similar
results were obtained, and unless otherwise stated,
data from representative experiments are presented.
Within experiments, each condition was tested on 12
explants, and the results expressed for purpose of
clarity as the mean"S.E.M.. Results were analysed
statistically using the two-tailed Mann–Whitney U-
test for non-parametric data.
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3. Results
3.1. Bo˝ine nasal cartilage
We first examined the rate of hydolysis of extra-
cellular ATP by bovine nasal cartilage explants. The
amount of ATP in the culture media decreased
steadily with time as judged by the decrease in the
ATP peak following anion-exchange chromatography
 .data not shown . The t of extracellular ATP was0.5
found to be 5.3 h. We could detect no hydrolysis of
ATP in the absence of explants over the time period
measured, nor could we detect any ATP present in
the medium of cultures to which no extracellular
ATP had been added.
w xIn agreement with our earlier findings 10 , ATP-
stimulated proteoglycan release in a dose-dependent
manner and the minimum effective initial concentra-
 .tion was 250 mM Fig. 1 . Typically an initial con-
centration of 500 mM ATP produced at least a dou-
bling of proteoglycan release compared to control
and was therefore, used in all subsequent experi-
ments. Equivalent amounts of proteoglycan release
Fig. 1. Dose-response for the stimulation of proteoglycan release
by ATP from bovine nasal cartilage explants. Cartilage explants
were cultured for 5 days in DMEM with or without varying
concentrations of ATP added at time 0. )) p-0.005; ))) p-
0.0005 compared to control.
Fig. 2. The effect on nasal cartilage proteoglycan release of
 .different times of exposure to ATP. ATP 500 mM was added to
explants at the start of the experiment and removed after the
indicated times. The cartilage discs were then washed in DMEM
and cultured for the remainder of the 5 days in DMEM alone.
))) p-0.0005 compared to control.
occurred whether 500 mM ATP was added on a daily
 .basis 62"3% of total sGAG released or once at
the start of the experiment 68"3% of total sGAG
.released . Thus, in subsequent experiments only a
single initial dose of ATP was added.
ATP was required in the culture media for at least
8 h to influence proteoglycan release, and increasing
the time that ATP was present up to 24 h, signifi-
cantly increased the amount of proteoglycan released
 .by the explants Fig. 2 . This result is surprising in
view of the lability of ATP in the cartilage cultures
 .above .
As with TNFa- and Ret-stimulated release, the
time course of proteoglycan loss following ATP
treatment was slower than following rhIL1a treat-
ment. Although there was some variability between
animals, greater than 50% release of total proteogly-
can was usually achieved by 5 days of culture with
 .Ret, rhTNFa and ATP Fig. 3 .
As ATP is rapidly hydrolysed to ADP and AMP,
experiments were performed to verify that the ob-
served stimulation of cartilage resorption was not due
to the action of metabolites of ATP acting at P -1
( )C.J. Brown et al.rBiochimica et Biophysica Acta 1362 1997 208–220 213
Fig. 3. Time-course of proteoglycan release from bovine nasal cartilage explants cultured with or without various catabolic agents.
Explants were cultured for up to 5 days in DMEM with or without rhIL1a , rhTNFa , Ret, or ATP, after which the medium and explants
 .were analysed for sGAG content. Percentage proteoglycan release for all catabolic agents is significantly different to control p-0.005 .
purinoceptors. Firstly, we confirmed previous work
showing that ADP and AMP failed to increase the
basal level of proteoglycan release Table 1, column
.1 . To further establish that ATP was not acting via
P -purinoceptors we investigated the effects of 8-1
phenyltheophylline, a competitive P -purinoceptor an-1
w xtagonist 23 , on ATP-stimulated sGAG release. Due
to its limited solubility, 8-phenyltheophylline was
used at 10 mM. However, this concentration is above
w xits IC 24 , and the percentage total sGAG release50
 .elicited by ATP 35.3"5.2 was not altered by its
 .  .presence 34.9"4.4 . ATPgS 500 mM , an ATP
analogue that is less readily metabolised than ATP
and that acts through P -purinoceptors, also increased2
the percentage total sGAG released from 17.5"1.3
 .  .control to 28.6"3.7 p-0.005 .
ADP or AMP significantly inhibited the stimula-
tory effect of ATP on proteoglycan loss when both
agents were added at the start of the culture Table 1,
.columns 2 and 3 . However, the inhibitory effects of
ADP and AMP were not observed when they were
added 24–48 h after the explants were treated with
Table 1
Inhibition of ATP-stimulated proteoglycan release from bovine nasal cartilage by ADP and AMP
Addition % sGAG Addition % sGAG Addition % sGAG
released released released
 .  .None 20.2"1.6 ATP Day 0 43.3"3.8 ATP Day 0 43.3"3.8
b a .  .  .  .  .ATP Day 0 43.3"3.8 ATP Day 0 qADP Day 0 29.2"2.9 ATP Day 0 q AMP Day 0 27.9"4.6
 .  .  .  .  .ADP Day 0 21.3"2.2 ATP Day 0 qADP Day 1 34.8"2.4 ATP Day 0 q AMP Day 1 46.9"5.6
 .  .  .  .  .AMP Day 0 18.7"1.9 ATP Day 0 qADP Day 2 47.5"6.2 ATP Day 0 q AMP Day 2 36.7"3.1
 .Cartilage explants were cultured in DMEM for 5 days. Where appropriate, ATP 500 mM was added at the start of the incubation, and
 .ADP or AMP 500 mM were added on days 0, 1 or 2. The percentage of total sGAG released over 5 days was determined and results are
 .expressed as the mean"S.E.M. ns12 .
a p-0.05.
b p-0.005 compared with ATP only.
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 .ATP Table 1, columns 2 and 3 . In a separate
experiment, we demonstrated that the inhibitory ef-
fect of AMP was not prevented by 8-phenyltheophyl-
line. The percentage total sGAG release elicited by
ATPqAMP was 23.1"3.5 and 24.8"4.1 in the
presence and absence of the antagonist respectively,
 .and both values were significantly lower p-0.05
 .than that obtained with ATP alone 35.3"5.1 .
Addition of ATP to cartilage explants led to an
increase in PGE released into the conditioned
medium, from 0.23"0.04 pgrmg of total sGAG to
 .1.83"0.46. pgrmg of total sGAG p-0.01 .
It has been demonstrated that extracellular ATP
w xcauses release of IL1b from macrophages 25 . It
therefore seemed plausible that ATP might effect
proteoglycan release from nasal cartilage explants via
a similar pathway in which the chondrocytes were
reacting in an autocrine fashion to IL1. We investi-
gated this possibility by the use of IL1ra. A 500-fold
molar excess of IL1ra over rhIL1a completely inhib-
ited cytokine-mediated proteoglycan release data not
.shown . However, when proteoglycan breakdown was
stimulated by ATP, a similar high concentration of
IL1ra had no effect on the percentage of total sGAG
released 35"3.7 versus 33.4"4 in its presence and
.absence, respectively . It would, therefore, appear
that the catabolic effect of extracellular ATP on
proteoglycan release is independent of the binding of
endogenous IL1 to its receptor.
In addition to their stimulatory effects on proteo-
glycan release from cartilage, the catabolic reagents
IL1a , TNFa and Ret inhibit proteoglycan synthesis
w xby chondrocytes 26–28 . We therefore examined the
effect of ATP on incorporation by nasal cartilage
explants of 35SO into CPC-precipitable material with4
or without rhIL1a . ATP suppressed the basal level of
35 SO incorporation 17600"2900 cpmrdisc with4
.ATP and 24100"3400 cpmrdisc without ATP , but
the decrease was not statistically significant. ATP
also did not influence rhIL1a-inhibited 35SO incor-4
poration 4500"620 cpmrdisc with ATP and 5200
."500 cpmrdisc without ATP .
Proteoglycan release elicited by other resorptive
agents can be inhibited by inhibitors of metallo-,
w xcysteine- and serine-proteinases 11,13,14,29,30 . We
therefore examined the effects of proteinase in-
hibitors on ATP-stimulated proteoglycan release. For
these experiments, the incubation period was reduced
to 2 days so that results could be compared with
those for IL1a-stimulated release. The non-selective
matrixin inhibitors BB94, BB87 and BB250 signifi-
 .cantly inhibited ATP-stimulated release Table 2 ,
whereas the two inhibitors selective for the inhibition
of gelatinases, BB2001 and BB3003, failed to do
this. These results are very similar to those previously
w xobtained with TNFa , IL1 or Ret as the stimulus 11
and point to the involvement of a metallo-proteinase
other than a gelatinase in ATP-driven proteoglycan
breakdown.
We have previously found that matrixin activity,
remains low during the time-course of nasal cartilage
proteoglycan release stimulated by cytokines and Ret
w x11 . ATP also failed to increase these low levels
which remained -2.5 pmol productrminrexplant.
In contrast, matrixin activity has been shown to
increase dramatically during later periods of culture
w xwith IL1, when collagen breakdown is occurring 31 .
The general membrane-permeant proinactivator of
w xcysteine-proteinases Ep453 32 , the specific proinac-
w xtivator of cathepsin B, CaO74Me 33 , and ACITIC,
an inactivator of serine-proteases with trypsin-like
w xspecificity 34 inhibited ATP-stimulated proteogly-
 .can release Table 2 . Further studies revealed that
Table 2
Effect of proteinase inhibitors on ATP-stimulated proteoglycan
release from bovine nasal septum cartilage









Cartilage explants were cultured with or without ATP and pro-
teinase inhibitor for 2 days. In the analysis of stimulated release,
basal levels were subtracted. Within experiments the percentage
inhibition was calculated for each inhibitor, and results from two
experiments were combined and expressed as the mean"S.E.M.
 .for the sake of clarity ns24 . Values of greater than 100%
reflect inhibition of basal as well as stimulated release. The
negative value indicates increased release compared to control
without proteinase inhibitor.
a p-0.05.
b p-0.0005 compared with control ATP without proteinase
.inhibitor .
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the minimum effective concentrations of CaO74Me
and ACITIC were 1 nM and 1 pM, respectively.
BB250 was effective at concentrations down to 1 mM.
These values are similar to those previously obtained
for the inhibition of proteoglycan release induced by
w xinflammatory cytokines 11,14,30 .
The loss of aggrecan from cartilage both in normal
and diseased states, and in tissue culture models,
results partly from cleavage in the interglobular re-
w xgion at a Glu-Ala bond 19,35,36 . The enzyme
thought to be responsible for this cleavage, termed
‘aggrecanase’, has not yet been identified. Thus, the
ability of ATP to bring about cleavage of bovine
nasal cartilage aggrecan at this major ‘aggrecanase’
cleavage site was investigated. The conditioned me-
dia from control and ATP-stimulated explants con-
tained aggrecan fragments of similar sizes detected
  ..using the 3B3 antibody Fig. 4 a . The larger aggre-
can fragments were found to contain the neoepitope
produced by ‘aggrecanase’ action, detected with the
  ..BC3 antibody Fig. 4 b , and more reaction product
was detected following incubation with ATP than in
  . .the control compare Fig. 4 b , lanes 1 and 2 . Al-
though this method of detection is at best semi-
quantitative, the presence of aggrecan fragments con-
taining this new N-terminal neoepitope Ala-Arg-
.Gly-Ser following treatment with extracellular ATP
implicates ‘aggrecanase’ in the resulting aggrecan
breakdown. It is already established that increased
aggrecan breakdown resulting from treatment with
w x w xIL1, Ret 14 and TNFa 37 results at least in part
from the action of ‘aggrecanase’. We conclude that
the proteolytic events following ATP treatment of
nasal cartilage are very similar to those that occur in
response to the cytokines TNF and IL1, and involve a
number of proteinases in an activation cascade that
results in the cleavage of aggrecan by ‘aggrecanase’.
Since extracellular ATP is cytotoxic to some cell
w xtypes 25,38 , we measured its effect on various
metabolic activities of the explants. Chondrocytes are
w xknown to respire largely anaerobically 39 , so that
the rate of production of lactate can be used as a
measure of the general metabolic activity of the cells.
In addition, treatment with other agents that cause
increased proteoglycan breakdown increases lactate
production. IL1 increases lactate production by fi-
w x w xbroblasts 40 and rheumatoid synovial cells 41 in
w xcell culture, and by cartilage in organ culture 42 .
Fig. 4. Analysis of aggrecan core protein fragments. Samples
 .20 ml, equivalent to 32 ml of conditioned medium were sub-
jected to electrophoresis on 4–10% gradient polyacrylamide gels
in the presence of SDS after deglycosylation of the aggrecan
fragments. The samples were electro-transferred to PVDF mem-
 .  .branes and stained with 3B3 a or BC3 b antibodies to detect
chondroitin-6-sulfate stubs, and the ARGS N-terminal sequence
of fragments produced after cleavage at the ‘aggrecanase’ cleav-
age site, respectively. Lane 1, conditioned medium from control
explants incubated in DMEM only; Lane 2, conditioned medium
 .from ATP-stimulated 500 mM explants.
Similarly, Ret has been found to increase rates of
glycolysis in embryonic chick limb cartilage cultures
w x43 . We therefore analysed the influence of extracel-
lular ATP on lactate production by nasal cartilage
explants. ATP had no significant effect on lactate
production 215"10 mgrdisc in its presence versus
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Table 3
Effect of ATP and its metabolites on cytokine- and Ret-stimulated proteoglycan release in bovine articular cartilage
Cytokine Adenine nucleotide
None ATP None ATPgS None ADP AMP
a aNone 30"5 15"1 15"2 11"2 21"3 15"2 17"2
b brhIL1a 73"4 40"5 48"3 27"2 60"3 53"4 55"3
b brhTNFa 67"7 28"6 59"3 20"4 43"4 43"3 38"3
b bRet 71"4 34"4 69"3 24"3 63"4 59"4 68"4
 .  .  .  .Explants were cultured in DMEM with rhIL1a 2 nM , rhTNFa 7 nM or Ret 1 mM and with or without ATP 500 mM , ADP
 .  .  . a500 mM , AMP 500 mM or ATPgS 500 mM for 5 days. The values given are percentage of total sGAG released. p-0.05;
b p-0.0005 compared with no ATP or ATPgS.
.199"6 mgrdisc in its absence and it also failed to
modify the rhIL1a-induced increase in lactate release
310"9 mgrdisc versus 312"13 mgrdisc in the
.presence and absence of ATP, respectively .
In order to further investigate the possibility of
non-specific or toxic effects of extracellular ATP on
the explants, we measured the rates of protein synthe-
 . w35 xsis. ATP 500 mM had no effect on S -methionine
incorporation in nasal explants 6300"700 and 6500
"800 cpmrdisc in the presence and absence of ATP,
.respectively . These findings indicate that ATP was
not having a toxic effect on bovine nasal chondro-
cytes.
3.2. Bo˝ine articular cartilage
As with nasal cartilage, articular cartilage explants
also degraded exogenous ATP, and the calculated t0.5
was 3 h. No detectable endogenous ATP was released
into the culture medium by the cartilage explants.
 .In contrast to nasal cartilage, ATP 500 mM sig-
nificantly inhibited basal articular cartilage proteogly-
can release over a 5 day period, when added on a
daily basis % sGAG released was 27"1 and 56.9"
4 in the presence and absence of ATP, respectively;
.p-0.0005 . A single dose of ATP added at the start
of the incubation also reduced proteoglycan release to
 .35"4% p-0.005 , and this value was not signifi-
cantly different from that obtained when ATP was
replenished on a daily basis. Consequently, in subse-
quent experiments, ATP was added at the start of the
culture period only.
We next examined if ATP exerted an inhibitory
effect on proteoglycan release stimulated by proin-
flammatory cytokines and by Ret. In all cases, ATP
produced statistically significant inhibition Table 3,
.column 2 .
The calculated t values suggested that extracel-0.5
lular ATP was degraded more rapidly by bovine
articular cartilage explants than by nasal cartilage
explants. We therefore hypothesised that the differ-
ence in its action on articular cartilage might reflect
its faster conversion to ADP and AMP, and con-
ducted a number of experiments to explore this possi-
bility. Firstly, the poorly hydrolysable analogue
ATPgS-inhibited basal and stimulated proteoglycan
release in a manner analogous to that of ATP Table
.3, column 3 . Secondly, neither ADP nor AMP-in-
hibited basal proteoglycan release 20q3% total
sGAG released from untreated explants compared
with 18"2% and 18"2% from explants treated
.with ADP and AMP, respectively , although ADP
and AMP reduced the percentage total sGAG re-
leased in the presence of ATP from 14"2 to 9"1
and 10"2, respectively p-0.05 relative to value
.for ATP alone . ADP and AMP also had no effect on
cytokine- or ret-stimulated proteoglycan release Ta-
.ble 3, column 4 . Finally, the P antagonist, 8-phenyl-1
 .theophylline 10 mM , did not attenuate the inhibitory
effect of ATP 9.7"1.1% of total sGAG released
with ATP and 10.4"1.5% released with ATP and
8-phenyltheophylline, compared with 15.4"1.6% for
.control explants .
Further experiments were conducted to demon-
strate that ATP was not exerting a cytotoxic effect on
bovine articular chondrocytes. ATP had no signifi-
cant effect on the production of lactate by the articu-
lar explants, either in the presence or absence of
 .rhIL1a not shown . However, ATP significantly
increased proteoglycan synthesis measured as incor-
( )C.J. Brown et al.rBiochimica et Biophysica Acta 1362 1997 208–220 217
35 . poration of SO both in the absence 8500"4
900 cpmrdisc without ATP and 16300 "
.1100 cpmrdisc with ATP; p-0.0005 , and the pres-
ence of rhIL1a 2000"90 cpmrdisc without ATP
.and 2500"140 cpmrdisc with ATP, p-0.05 .
We conclude that the inhibitory effect of ATP on
articular cartilage proteoglycan release was not due to
a toxic effect. Indeed, in contrast to its effect on nasal
cartilage ATP is anabolic to articular cartilage ex-
plants, inhibiting proteoglycan breakdown and stimu-
lating its synthesis.
4. Discussion
Although direct release of ATP from articular and
nasal chondrocytes was not demonstrated in this
study, ADP and AMP have been found in condi-
tioned media from chick embryonic sternal chondro-
cytes and it has been suggested that they are derived
from released ATP, since added extracellular ATP is
w xrapidly hydrolysed in that system 44 . Damage to the
cartilage matrix could also lead to chondrocyte lysis
with subsequent release of the large amounts of
intracellular ATP. ATP may be released by chondro-
cytes through a selective channel, perhaps using the
multi-drug resistance gene product, P-glycoprotein,
which serves as a channel for steady release of ATP
w xfrom Chinese hamster ovary cells 45 . Other cells in
proximity to cartilage may release ATP. Vascular
endothelial cells, T cells, macrophages and erythro-
cytes have been shown to release ATP, in some cases
w xin response to addition of extracellular ATP 46–48 .
The results presented here are in agreement with
earlier work demonstrating that extracellular ATP
enhances nasal cartilage explant proteoglycan break-
w xdown 10 . The rapid breakdown of ATP in our
culture systems may necessitate the addition of much
higher concentrations than might be required if a
constant concentration could be maintained. How-
ever, our data suggest that a single high dose of ATP
is sufficient to cause a long-term change in the
phenotype of the chondrocyte, as the chondrocytes
continue to respond long after the ATP is hydrolysed
or has been removed by a medium change. A previ-
ous report has indicated that chondrocytes undergo a
long-term change in phenotype in response to IL1
w x31 . The antagonistic effects of ADP and AMP
which only occurred within the first 24 h of culture
supports the latter suggestion.
Only P -purinoceptors appear to be involved in the2
stimulation of proteoglycan release, as ATP metabo-
lites which may signal through P -purinoceptors failed1
to induce proteoglycan release in nasal cartilage, and
8-phenyltheophylline, a P -purinoceptor antagonist,1
had no effect on ATP-stimulated proteoglycan re-
lease. ATPgS, a relatively stable form of ATP that
acts through P -purinoceptors, stimulated nasal pro-2
teoglycan breakdown.
The mechanism by which ATP binding to its
receptors stimulates proteoglycan release from nasal
cartilage is unknown. It was considered possible that
ATP was acting indirectly by stimulating release of
proinflammatory cytokines such as IL1, since ATP
and IL1 have similar effects on some chondrocyte
actions, and ATP is known to lead to the release of
w xIL1b from macrophages 25 . Both reagents stimulate
proteoglycan release and release of PGE from bovine
nasal cartilage explants. Moreover, CaO74Me inhib-
ited both ATP- and IL1-stimulated proteoglycan re-
lease. However, we have clearly shown that extracel-
lular ATP is not acting via the release of endogenous
IL1 since IL1ra failed to prevent ATP-stimulated
proteoglycan release. In addition, unlike IL1, ATP
failed to increase lactate production or inhibit proteo-
glycan synthesis in nasal cartilage. An indirect action
Table 4
Some effects of resorptive agents on nasal chondrocyte-mediated activities
PGE release Proteoglycan Aggrecanase Inhibition Lactate
synthesis involvement by CaO74Me production
IL1 Increased Decreased Yes Yes Increased
TNF Increased Decreased Yes Yes Increased
Ret Increased Decreased Yes No Increased
ATP Increased No effect Yes Yes No effect
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of other cytokines such as TNFa cannot be ruled out,
although none of the agents which stimulate proteo-
glycan release directly mirror the response of ATP in
nasal cartilage. Table 4 compares the effect of each
reagent on various activities of bovine nasal cartilage.
ATP failed to enhance the low level of matrixin
activity present in the culture medium during the
time-course of proteoglycan breakdown, despite the
inhibition of breakdown by potent matrixin inhibitors.
These results suggest that the known matrixins do not
play a major role in ATP-stimulated proteoglycan
breakdown, as also appears to be the case following
w xIL1, TNF and Ret treatment 11 .
The studies reported here represent the first
demonstration that exogenous ATP inhibits proteo-
glycan release from articular cartilage explants. Both
ADP and AMP had no effect on basal proteoglycan
release in articular cartilage but enhanced the re-
sponse to ATP when added concurrently. Addition of
these metabolites may inhibit the action of ATPases
 .product inhibition , thus increasing the effective con-
centration of ATP. Indeed ADP has been shown to
inhibit formation of inorganic pyrophosphate from
added ATP in monolayer cultures of human articular
w xchondrocytes 49 .
The reasons for the opposite effects of ATP in the
two cartilage types remain unclear. Bovine nasal
cartilage is sparsely vascularised, whereas articular
cartilage is usually avascular and it is possible that
the action of ATP on nasal cartilage endothelial cells
leads to proteoglycan degradation. Alternatively, de-
pending on the source of the chondrocytes, ATP may
act through different receptor subtypes whose sig-
nalling cascades have differing effects. The increase
in PGE synthesis in cartilage and similar agonist
profiles for the PGE and resorptive responses do not
suggest the involvement of different receptor sub-
types, but further work is needed to confirm this. If
ATP does act on the same receptor subtype in both
cases, it is still possible that the resulting signalling
pathways lead to different responses in each cartilage
type.
The differences between nasal and articular carti-
lage with respect to the effect of extracellular ATP on
proteoglycan breakdown may suggest a role for this
agent in diseases which lead to increased breakdown
of non-articular cartilage, such as relapsing polychon-
w xdritis and inflammatory airways diseases 50,51 . In
articular cartilage, extracellular ATP may act anaboli-
cally, inhibiting breakdown and stimulating synthesis
of proteoglycan, thus contributing to the repair pro-
cess in arthritis.
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